Federated Hermes, Inc. Concert Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $6.36 $669 - $1,520	-239 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.73 - $3.94 $5,528 - $7,978	-2,025 Reduced 89.44%	239 $1,000
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $1,046 - $1,641	-389 Reduced 14.66%	2,264 $7,000
Q3 2021 Nov 15, 2021	SELL	$3.17 - $4.15 $9 - $12	-3 Reduced 0.11%	2,653 $9,000
Q2 2021 Aug 16, 2021	BUY	$3.77 - $5.24 $10,013 - $13,917	2,656 New	2,656 $11,000
Q1 2021 May 13, 2021	SELL	$4.86 - $13.07 $578 - $1,555	-119 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$9.48 - $12.84 $255 - $346	27 Added 29.35%	119 $2,000
Q3 2020 Nov 12, 2020	SELL	$8.67 - $10.82 $24,354 - $30,393	-2,809 Reduced 96.83%	92 $1,000
Q2 2020 Aug 13, 2020	BUY	$7.8 - $11.52 $14,593 - $21,553	1,871 Added 181.65%	2,901 $29,000
Q3 2018 Nov 13, 2018	SELL	$12.82 - $17.88 $413,201 - $576,290	-32,231 Reduced 96.9%	1,030 $15,000
Q2 2018 Aug 10, 2018	BUY	$16.83 - $21.66 $7,405 - $9,530	440 Added 1.34%	33,261 $560,000
Q1 2018 May 09, 2018	BUY	$19.24 - $28.03 $209,677 - $305,470	10,898 Added 49.71%	32,821 $752,000
Q4 2017 Feb 14, 2018	BUY	$13.96 - $29.05 $306,045 - $636,863	21,923	21,923 $0

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.